SciBase Holding AB (OSTO:SCIB) Total Premiums Earned

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SCIB SciBase Holding AB OSTO:SCIB
47 GF Score
Price kr27.90
GF Value kr20.19
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is SciBase Holding AB Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.

OSTO:SCIB
47GF Score
SciBase Holding AB OSTO:SCIB
Total Premiums Earned is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?

Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued. The current stock price of kr27.90 is trading 38.2% above its estimated GF Value™ of kr20.19. GuruFocus considers SciBase Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:SCIB:

  • Total Premiums Earned:
  • GF Value™: kr20.19 vs. price of kr27.90 (38.2% above fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SciBase Holding AB Business Description

Address Landsvagen 39, Sundbyberg, Stockholm, SWE, 172 63
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
47GF Score

Get the complete analysis for OSTO:SCIB

Total Premiums Earned is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr27.90
Price
kr20.19
GF Value